Trademark Overview
On Monday, February 2, 2026, a trademark application was filed for TELVOLZY with the United States Patent and Trademark Office. The USPTO has given the TELVOLZY trademark a serial number of 99628033. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, June 23, 2026. This trademark is owned by Elixirgen Therapeutics, Inc.. The TELVOLZY trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells
